Comparative efficacy of opicapone and entacapone in the management of motor fluctuations in Parkinson’s disease
Objective: To compare the clinical efficacy of two catechol-O-methyltransferase (COMT) inhibitors, opicapone (OPC) and entacapone (ENT). Background: OPC and ENT are used as adjunctive therapy…Methodological considerations supporting a time-to-event primary endpoint in the PADOVA study in early-stage Parkinson’s disease participants on stable symptomatic treatment
Objective: To provide the methodological rationale for using a time-to-event (TTE) primary endpoint in the PADOVA study. Background: The use of symptomatic medications represents a…Continuous subcutaneous foslevodopa/foscarbidopa infusion therapy leads to a sustained reduction in dyskinesias in Parkinson’s disease
Objective: To assess the longitudinal effect of continuous subcutaneous foslevodopa/foscarbidopa infusion therapy on dyskinesias as measured by the Unified Dyskinesia Rating Scale (UDysRS) total score…Targeting inflammation and autophagy: a dual-inhibition strategy to reduce α-synuclein pathology in GBA1-associated Parkinson’s disease
Objective: To assess the effects of combined inhibition of mTOR (autophagy regulator) and STING (inflammation regulator) on α-synuclein phosphorylation, tyrosine hydroxylase expression, and lysosphingolipid levels in…Findings of motoric and neuro psychological outcome using high frequency stimulations in Parkinsons with STN-DBS
Objective: For testing the likelihood of decreasing psychiatric dyskinesias of STN-DBS, conducting experimentally and through experimental studies we explore the properties of in what best…Natural compound Protects Dopaminergic Neurons by Targeting Oxidative Stress and Cell Death Pathways in Parkinson’s Disease
Objective: This study aims to evaluate the neuroprotective potential of a natural compound that protects dopaminergic neurons by targeting oxidative stress and cell death pathways…The Effects of Melatonin in Parkinson’s Disease: A Systematic Review and Meta-Analysis of Double-Blind, Placebo-Controlled RCTs
Objective: To assess the efficacy of melatonin on motor symptoms, sleep quality, and quality of life in patients with Parkinson's disease (PD) by performing a…Dosage Optimization and Treatment Outcomes of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson’s Disease: a single center study
Objective: To optimize the dosage of foslevodopa/foscarbidopa continuous subcutaneous infusion (CSCI) therapy for Parkinson’s disease by identifying dosage differences between the continuation and discontinuation groups.…Patient And Clinician Perceptions Of Disease Improvement With Levodopa–Entacapone–Carbidopa Intestinal Gel (LECIG) In Advanced Parkinson’s – Data From The ELEGANCE Interim Analysis
Objective: To evaluate clinicians’ and patients’ views of the level of improvement in Parkinson’s disease (PD) achieved following up to two years of treatment with…Comparative Efficacy and Safety of Opicapone in Parkinson’s Disease: An Updated Systematic Review and Meta-Analysis
Objective: To evaluate the efficacy and safety of Opicapone drug in patients with Parkinson’s disease (PD) using an updated systematic review and meta-analysis, including newly published randomized controlled trials…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 436
- Next Page »